Moleculin Biotech, Inc. (MBRX) Stock Price, Financials & Summary

Price chart

Aug 19Aug 24Aug 27Sep 1Sep 4Sep 10Sep 15Sep 18

Key dataSep 18, 2026

Open$0.78

From 52W high−94.17%

Volume421622.00

Market cap$15.06M

P/E (TTM)—

P/S (TTM)—

Div yield—

Key dataSep 18, 2026

Open

$0.78

From 52W high

−94.17%

Volume

421622.00

Market cap

$15.06M

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

−0.3x

P/E (TTM)

—

RSI (14)

47.8

MomentumView details →

1D Return

−0.88%

YTD Return

−76.52%

SummaryUpdated Jun 1, 2026

Moleculin Biotech, Inc. (NASDAQ:MBRX) is a clinical-stage pharmaceutical company founded in 2015 and headquartered in Houston, Texas. The company went public in June 2016 and focuses on developing innovative drug candidates specifically designed to treat highly resistant tumors and viruses. Moleculin operates in the biotechnology sector within the broader healthcare industry, positioning itself as a specialized developer of oncology therapeutics with a particular emphasis on addressing unmet medical needs in cancer treatment where existing therapies have failed or proven inadequate.

Ask drillr about Moleculin Biotech, Inc. →

ValuationView details →

P/E (Fwd)

—

P/E (TTM)

—

EV/EBITDA

−0.3x

EV/Sales

—

P/S (TTM)

—

P/B (TTM)

1.3x

ProfitabilityView details →

Gross Margin

—

Net Margin

—

EBITDA Margin

—

ROE (TTM)

−261.73%

ROA (TTM)

−143.82%

Asset Turnover

0.00x

GrowthView details →

Revenue YoY

—

EPS YoY

+84.89%

FCF YoY

−18.81%

Revenue CAGR 3Y

—

EPS CAGR 3Y

+84.97%

EBITDA YoY

−31.52%

MomentumView details →

1D Return

−0.88%

YTD Return

−76.52%

1Y Return

−92.28%

RSI (14)

47.8

vs 50D SMA

−25.37%

vs 200D SMA

−70.78%

Capital & dividendView details →

Debt/Equity

0.03x

Current Ratio

0.94x

Quick Ratio

0.94x

Div Yield

—

Div Rate

—

Div Growth 1Y

—

EarningsView details →

EPS (Actual)

−$1.40

EPS Surprise

9.68%

Beats (12Q)

8/12

Next Q EPS Est

−$0.44

Avg Surprise (4Q)

32.88%

Rev Surprise

—

Financials snapshotView financials →

Revenue (TTM)

0.00

Net Income (TTM)

−30.33M

Op. CF (TTM)

−25.36M

Next earningsNov 12, 2026 →

Latest newsMore news →

Moleculin announced it will present new Annamycin data at the AACR Conference on Pancreatic Cancer and two European scientific meetings.6d ago

Similar companies

Daré Bioscience, Inc.DARE Passage Bio, Inc.PASG Hoth Therapeutics, Inc.HOTH Vyome Holdings, Inc.HIND Synlogic, Inc.SYBX SeaStar Medical Holding CorporationICU Find similar companies →

Latest newsMore news →

Moleculin Biotech, Inc. received a Nasdaq notice dated September 15, 2026 for failing to comply with the minimum bid price requirement under Rule 5550(a)(2) and intends to request a hearing before the Nasdaq Hearings Panel.2d ago Moleculin announced it will present new Annamycin data at the AACR Conference on Pancreatic Cancer and two European scientific meetings.6d ago